Spondyloarthritis & psoriatic arthritis
Race, Ethnicity, and Geographic Diversity in Pivotal Psoriatic Arthritis Clinical Trials: Further Progress Needed
Authors' conclusion
Racial and ethnic diversity in pivotal PsA trials remains limited.
Study context
- Population
- Pivotal trials of b/tsDMARDs approved for psoriatic arthritis (PsA) in the United States, start dates 2000–201929 trials
- Outcome
- Reporting and representation of race, ethnicity and geographic distribution of trial sites
Methodological details29 pivotal PsA trials for 16 targeted therapies, Data from journal publications, the Drugs@FDA database and ClinicalTrials.gov
- 29 pivotal PsA trials for 16 targeted therapies
- Data from journal publications, the Drugs@FDA database and ClinicalTrials.gov
Main finding
As reported in the abstract
Reporting and representation of race, ethnicity and geography
- Trials reporting race data
- 93%
- Race reporting in journal publications
- 86%
- Of journal publications reporting race, reporting only proportion of White participants
- 46%
- Trials with ethnicity data (primarily ClinicalTrials.gov; improved in recent years)
- 41%
- White participants (14,165 participants, 27 trials with race data)
- 92%
- Asian participants
- 7%
- Black, American Indian/Alaska Native, or Native Hawaiian/Pacific Islander participants
- fewer than 1%
- Hispanic or Latino participants (8,105 participants, 12 trials with ethnicity data)
- 11%
- Trials with location data
- 26
- US trial activity: Texas (24 trials), Florida and Pennsylvania (22 each), California (20); correlation with state population size
- r = 0.78, P < 0.0001
- Countries with trial sites (primarily North America and Europe; fewer in Asia, Africa, Latin America)
- 55
Original publication
Race, Ethnicity, and Geographic Diversity in Pivotal Psoriatic Arthritis Clinical Trials: Further Progress Needed. Arthritis Care Res (Hoboken). Published 1 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →